Bayer Supports Claritin-D Indications Claim, Not Superiority Over GSK's Flonase
Executive Summary
Bayer supports making an “8 versus 6 FDA-approved indications” comparison with GSK's Flonase ,but it fails when suggesting Flonase doesn't relieve "sinus congestion and pressure” and “itchy throat” based only on GSK's competing product not receiving FDA approval for those indications, says NAD.
You may also be interested in...
Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.